Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
106.28
-2.13 (-1.96%)
Feb 21, 2025, 4:00 PM EST - Market closed
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $467.17M in the quarter ending September 30, 2024, with 40.79% growth. This brings the company's revenue in the last twelve months to $1.64B, up 48.45% year-over-year. In the year 2023, Sarepta Therapeutics had annual revenue of $1.24B with 33.26% growth.
Revenue (ttm)
$1.64B
Revenue Growth
+48.45%
P/S Ratio
6.28
Revenue / Employee
$1,248,362
Employees
1,314
Market Cap
10.15B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
Dec 31, 2019 | 380.83M | 79.80M | 26.51% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SRPT News
- 3 days ago - 20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset' - Market Watch
- 8 days ago - Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility - Business Wire
- 10 days ago - Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results - Business Wire
- 12 days ago - Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics - Business Wire
- 26 days ago - Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS - Business Wire
- 5 weeks ago - Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely - Seeking Alpha
- 5 weeks ago - Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue - Business Wire
- 6 weeks ago - Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference - PRNewsWire